INNOVENT BIOLOGICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.2 HKD | +1.09% |
|
+4.05% | -12.87% |
| Sales 2024 * | 7.58B 1.05B 8.18B | Sales 2025 * | 9.95B 1.38B 10.74B | Capitalization | 55.49B 7.67B 59.89B |
|---|---|---|---|---|---|
| Net income 2024 * | -836M -115M -902M | Net income 2025 * | 54M 7.46M 58.29M | EV / Sales 2024 * | 6.69 x |
| Net cash position 2024 * | 4.79B 662M 5.17B | Net cash position 2025 * | 4.16B 575M 4.5B | EV / Sales 2025 * | 5.16 x |
| P/E ratio 2024 * |
-65.4
x | P/E ratio 2025 * |
716
x | Employees | 4,872 |
| Yield 2024 * |
-
| Yield 2025 * |
0.01% | Free-Float | 92.93% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +6.98% | ||
| Current month | +4.55% | ||
| 1 month | -10.02% | ||
| 3 months | -11.75% | ||
| 6 months | -12.90% | ||
| Current year | -13.92% |
1 week
34.10
36.95
1 month
34.1041.80
Current year
28.3046.15
1 year
27.3049.80
3 years
18.0694.75
5 years
18.06107.10
10 years
14.00107.10
| Managers | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CEO | Chief Executive Officer | 61 | 11-04-27 |
Fei You
DFI | Director of Finance/CFO | 45 | Feb. 04 |
Yong-Jun Liu
PSD | President | - | 20-10-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Zieziula
BRD | Director/Board Member | 69 | 22-05-30 |
Charles Cooney
BRD | Director/Board Member | 80 | 15-10-17 |
De Chao Yu
CEO | Chief Executive Officer | 61 | 11-04-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.78% | 2 M€ | -17.32% | - | |
| 1.77% | 4 M€ | -27.92% | ||
| 1.09% | 1 M€ | -9.86% | - | |
| 0.68% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 37.2 | +1.09% | 2 406 509 |
| 24-06-04 | 36.8 | +6.98% | 6,566,248 |
| 24-06-03 | 34.4 | -2.27% | 5,078,754 |
| 24-05-31 | 35.2 | -0.14% | 9,758,852 |
| 24-05-30 | 35.25 | -1.54% | 3,789,772 |
Delayed Quote Hong Kong S.E., June 04, 2024 at 04:08 am EDT
More quotes
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkinâs lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
34.1
CNY
Average target price
51.13
CNY
Spread / Average Target
+49.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.92% | 7.16B | |
| -0.63% | 90.85B | |
| -0.92% | 39.02B | |
| -9.57% | 33.46B | |
| -17.98% | 14.51B | |
| -6.74% | 13.22B | |
| -9.76% | 11.65B | |
| -47.31% | 10.57B | |
| +6.52% | 9.23B | |
| +137.06% | 7.71B |
- Stock Market
- Equities
- 1801 Stock
